Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,600 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Skin Patch Clear all

Conditions: Tobacco Dependence
Interventions: nicotine patch, nicotine lozenge, bupropion, patch + lozenge, bupropion + lozenge; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Restless Legs Syndrome
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more

Conditions: Healthy
Interventions: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Vitiligo
Interventions: Needling, Triamcinolone; Procedure · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Pain, Postoperative
Interventions: DMTS Patch, Placebo Patch; Drug
Lead sponsor: Teikoku Pharma USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Anaheim, California • Salt Lake City, Utah

Conditions: Angiofibroma of Face, Tuberous Sclerosis
Interventions: Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment; Drug
Lead sponsor: Aucta Pharmaceuticals, Inc; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: Smoking Cessation
Interventions: Nicotine Replacement Therapy (NRT), Questionnaire, Counseling, Self-Help Materials; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Skin Cancer
Interventions: Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra; Device · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking Cessation
Interventions: Motivational Interviewing (MI), Nicotine Replacement Therapy (NRT), Nicotine Lozenge, Message Framing, saliva sample; Behavioral · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • Walnut Creek, California • La Grange, Georgia + 14 more

Conditions: Smoking, Homeless Persons
Interventions: Bupropion, Nicotine replacement therapy, Contingency Management; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dysphagia, Stroke
Interventions: Microphone device; Device
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes
Interventions: PassPort(R) Transdermal Insulin Delivery System; Other
Lead sponsor: Altea Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: 387 Technology Circle, NW, Suite 100, Atlanta, Georgia

Conditions: Osteoarthritis of the Knee
Interventions: Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Melanoma
Interventions: EGIR Tape; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Motion Sickness
Interventions: Scopolamine Nasal Gel, Placebo; Drug · Other
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 55 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: San Diego, California • Stanford, California • Chicago, Illinois + 6 more

Conditions: Dysplastic Nevi
Interventions: Saucerization biopsy; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Postoperative Pain, Obstetric Pain, Opioid Use
Interventions: Lidocaine patch, Placebo patch; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Skin Simulation Model, Mastery Learning Model to Simulation Training for Visual Screening for Melanoma and Skin Biopsy
Interventions: Simulation teaching session; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine
Interventions: Rotigotine patch; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 51
States / cities: Birmingham, Alabama • Cullman, Alabama • Fairhope, Alabama + 46 more

Conditions: Abortion
Interventions: timing of initiation of transdermal patch after an abortion; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 298 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Conditions: Rotavirus Infections
Interventions: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo; Biological · Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acne, Melasma, Rosacea, Seborrheic Dermatitis
Interventions: No Intervention; Other
Lead sponsor: Integrative Skin Science and Research; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Smoking Cessation Intervention: Effectiveness in Primary Care

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Determinants of Smoking Cessation Among Latinos

SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Contingency Management for Smoking Cessation in Homeless Smokers

Dysphagia Study Using Novel Microphone Device

Transdermal Basal Insulin Patch Study in Type 1 Diabetes

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

The Prevention and Treatment of Nausea Associated With Motion Sickness

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi

Lidocaine Patches After Cesarean Section

Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma

Named Patient Program With Rotigotine Transdermal System

Trial of Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis